Aura Biosciences Shifts Focus to Ocular Oncology and Bel-sar

Aura Biosciences is narrowing its corporate strategy to focus exclusively on ocular oncology. The company is deprioritizing its bladder cancer program to concentrate resources on its lead investigational therapy, bel-sar. This tactical shift is intended to accelerate the company's path toward commercialization as it nears critical data milestones for its flagship asset.

"Pick one thing you’re going to be best in the world at and go all in," said Natalie Holles, President and Chief Executive of Aura Biosciences, during a presentation at the Morgan Stanley conference.

Advancing the CoMpass Trial

The company's growth strategy now centers on the Phase III CoMpass trial for bel-sar, which evaluates the therapy for the treatment of early-stage choroidal melanoma. According to a conference transcript, the trial is fully enrolled. Management anticipates reporting top-line data in the second half of 2026, with a final 24-month readout expected in 2028.

This transition away from secondary pipeline programs, such as its previous efforts in bladder cancer, is intended to preserve capital and streamline clinical execution. By focusing solely on its ocular oncology platform, Aura intends to address a specific patient population.

Market Scope and Financial Performance

Aura estimates that the addressable market for early choroidal melanoma encompasses approximately 8,000 patients annually across the United States and major European markets. This patient segment forms the core of the company's commercial projections.

As of September 18, 2026, Aura Biosciences (AURA) stock was trading at $6.44, down 2.28% for the day. The company's valuation remains tied to the clinical progress of bel-sar, as the firm transitions from a multi-program developer to a focused oncology player.

Strategic Implications for Ocular Oncology

The decision to prioritize bel-sar highlights the challenges biotech firms face in managing multi-asset pipelines during the capital-intensive Phase III stage. For Aura, the consolidation of resources is a mechanism to ensure the CoMpass trial reaches completion without the dilution of focus or funding that occurs when managing concurrent clinical programs. This shift leaves the company's performance dependent on the upcoming 2026 data readout, which will serve as an indicator of whether the drug can meet its regulatory and clinical endpoints.